Sepsis: a frequent, costly, and difficult-to-diagnose medical emergency
Sepsis and its social burden
49 million cases and 11 million deaths in 2017
$5.1B spent on treatment and diagnosis in 2024
6–8% annual market growth expected through 2030
$52B annual cost to U.S. healthcare systems in 2021
A critical unmet need
Clinicians lack a reliable, early biomarker to quickly diagnose and assess sepsis severity.
Early detection is essential to improve survival and reduce healthcare costs.
There is a pressing need for an efficient point-of-care test to evaluate patient severity as soon as they arrive in intensive care or emergency units.
It is essential to develop an efficient point-of-care marker to rapidly assess the clinical severity of patients upon admission to intensive care or emergency departments.
Pr Sami Hraiech
Our solution: The DYNARED technology
A mechanical marker that improves risk assessment and accelerates medical decision-making.
In-vitro diagnostic medical device measuring red blood cell deformability
Advanced imaging: flow-based analysis of more than 2,000 individual red blood cells
Classification of red blood cells as Deformable or Non-Deformable using an Artificial Intelligence algorithm
Patented biomarker: The fTT marker provides the proportion of deformable red blood cells in the blood
Our value proposition
With DYNARED technology, we empower clinicians with a rapid, high-performance decision-support tool to:
– Optimize public healthcare costs
– Improve early diagnosis and treatment outcomes
– Increase patient survival rates